Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT

JIANG-HUA DING1, LI-YA YUAN2 and GUO-AN CHEN3

1Hematology and Oncology Department, The No. 171st Hospital of PLA, Jiujiang, Jiangxi 332000; 2Hematology Department, Jiangxi Academy of Medical Science; 3Hematology Department, The 1st Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China

Received July 12, 2015; Accepted November 1, 2016

DOI: 10.3892/ol.2016.5472

Correspondence to: Dr Guo-An Chen, Hematology Department, The 1st Affiliated Hospital of Nanchang University, 17 Yongwai Zheng Street, Donghu, Nanchang, Jiangxi 330006, P.R. China E-mail: gachen923@hotmail.com

Key words: aspirin, bortezomib, multiple myeloma, survivin, B cell lymphoma-2, AKT phosphorylation

Abstract. In our previous study, it was found that aspirin (ASA) exerted antimyeloma actions in vivo and in vitro. The resistance to bortezomib (BTZ) in multiple myeloma (MM) is partly due to AKT activation and the upregulation of survivin induced by BTZ, which are the targets of ASA in gastric and ovarian cancer, respectively. Thus, the present study investigated the interaction between ASA and BTZ in MM and further clarified the underlying mechanisms. MM1.S and RPMI-8226 cell lines harboring the N- and K-Ras mutations, respectively, were treated with 2.5 mM ASA, 10 nM BTZ and ASA+BTZ for different durations. The proliferation and apoptosis of the cells were determined, and the underlying mechanisms governing the interaction of ASA and BTZ were examined in the MM cells. Treatment with ASA+BTZ caused higher rates of proliferative inhibition and apoptosis in the MM1.S and RPMI-8226 cells in time-dependent manner, compared with either agent alone. A drug interaction assay revealed the additive effect of ASA and BTZ on the myeloma cells. ASA alone inhibited the levels of phosphorylated AKT (p-AKT) and survivin, whereas BTZ alone augmented the levels of p-AKT and survivin. Of note, ASA markedly decreased the upregulation of p-AKT and survivin induced by BTZ. Treatment with ASA+BTZ significantly suppressed the level of Bcl-2, compared with either agent alone. ASA may potentiate the antimyeloma activity of BTZ against myeloma cells via suppression of AKT phosphorylation, survivin and Bcl-2, indicating the potential of ASA+BTZ in treating MM, particularly for cases of BTZ-refractory/relapsed MM.

Introduction

Multiple myeloma (MM) is a malignant neoplasia of plasma cells, which accounts for ~10% of all types of hematological cancer. According to the latest statistics, the annual incidence of MM was reported to be 20,450 cases and the mortality rate for MM was 11,090 cases/year in the USA in 2013 (1). In addition, MM has evolved as one of the major diseases affecting the aging population in China (2). At present, MM is the second most prevalent hematological malignancy following non-Hodgkin's lymphoma (2). Even with the introduction of immunmodulators, including thalidomide and lenalidomide, and proteasome inhibitors, including bortezomib (BTZ), over the last decade, the 5-year survival rate of patients in the USA with MM is only 42% (1). In addition, almost all patients with MM undergo relapse and refractory disease, predominantly due to drug resistance (3). Until now, MM remains an incurable disorder among hematological malignancies.

Patients with MM are at enhanced risk of thromboembolism due to disease-specific and treatment-specific risk factors, particularly when treated with thalidomide and lenalidomide (4,5). Thus, the prevention of thrombosis has become important in cases of MM. At present, no significant differences have been observed among the use of aspirin (ASA), low-dose warfarin and low-molecular weight heparin in thrombophrophylaxis (6). ASA may be the optimum candidate to prevent thromboembolism in patients with MM due to its merits in method of administration, safety and cost without the requirement for regular coagulation monitoring (7). ASA has been widely used for thrombophrophylaxis in patients with MM, particularly in cases treated with thalidomide or lenalidomide combinations.

An increasing number of studies have demonstrated that ASA possesses antineoplastic actions against a wide range of solid tumor types, including esophageal, breast, lung and gastric cancer, and colon cancer in particular (8-12). Currently, the underlying anticancer mechanisms of ASA have been ascribed to the inhibition of nuclear factor (NF)-kB, and the induction of apoptosis by caspase activation, interruption of extracellular signal-regulated kinase and epidermal growth factor receptor in various types of cancer (13-17). Our previous study found
that ASA exerted antiproliferative and pro-apoptotic activities in vivo and in vitro via the upregulation of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax), and the suppression of Bcl-2 and vascular endothelial growth factor (18).

The anti-myeloma effect of BTZ, the first proteasome inhibitor to be approved by the Food and Drug Administration of USA in 2003, is well-recognized. At present, BTZ has become the foundation of first- and second-line treatment in MM. The major mechanisms underlying the action of BTZ in MM include inhibition of the activation of NF-kB, upregulation of pro-apoptotic Noxa and the subsequent downregulation of anti-apoptotic Bcl-2 (19). However, the increasing administration of BTZ is associated with the development of drug resistance (20). There have been a number of explanations for the insensitivity to BTZ, including proteasome subunit β5 mutation, insulin growth factor-1 and the differentiation status of myeloma cells (21-23). The activation of AKT and upregulation of survivin induced by BTZ itself are the primary factors involved in the development of resistance to BTZ in MM (24). Coincidentally, survivin, Bcl-2 and AKT have been confirmed to be the targets of ASA in gastric, cervical and ovarian cancer, respectively (13,25,26).

In relation to the findings described above, the present study hypothesized that ASA in combination with BTZ may produce additive or synergistic effects in the treatment of MM. The aim of the present study was to investigate the interaction between ASA and BTZ in the MM1.S and RPMI-8226 myeloma cell lines, and clarify the underlying mechanisms through detecting the effects of ASA and BTZ on the Bcl-2, survivin and AKT proteins.

Materials and methods

**Drugs and reagents.** ASA (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) was dissolved in solution containing 10 N sodium hydroxide and adjusted to pH 7.0. BTZ (Selleck Chemicals, Houston, TX, USA) was dissolved in dimethyl sulfoxide at a final concentration of 50 µM.

All liquid culture media were acquired from Invitrogen; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The BCA protein assay kit was obtained from Beyotime Institute of Biotechnology (Nantong, China). Antibodies against GADPH and Bcl-2 were obtained from Goodhere Biotechnology Co., Ltd. (Hangzhou, China) and Sigma-Aldrich; Merck Millipore, respectively. Antibodies against Akt, p-Akt (Thr308) and p-Akt (Ser473) were obtained from CST Biological Reagents Company Limited (Shanghai, China). The secondary antibody was from EarthOx Company (San Francisco, CA USA). The EnoGene™ total protein extraction kit was acquired from Enogene (Nanjing, China). Phosphosafe™ extraction reagent was purchased from Merck Millipore. The chemiluminescent detection kit (Super-Signal West Femto substrate) was from Thermo Fisher Scientific, Inc.

**Cell culture.** The MM1.S cell line, harboring the K-Ras mutation, and RPMI-8226, harboring the N-Ras mutation, were selected, as the oncogenic mutations of the K- and N-Ras genes were found to exist in 50% of MM cases and correlated with aggressive disease, resistance to therapy and poor survival rates (27). The MM1.S human myeloma cell line was provided by Dr Lu-Gui Qiu (Hematology Hospital, Chinese Academy of Medical Science, Tianjin, China). The human MM cell line (RPMI-8226) was purchased from American Type Culture Collection (Manassas, VA, USA). The cells were cultured at 37°C in a water-saturated atmosphere of 95% air and 5% CO2 in RPMI-1640 medium supplemented with 10% heat-inactivated FBS (Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin. When indicated, the cells were seeded at a confluence of 80% (serum-free medium was the vehicle) in 96-well or 6-well plates and treated with vehicle or ASA.

**Cell proliferation assay.** The cells were harvested and seeded into 96-well plates (1x10^4 cells per well) in a total volume of 200 µl. According to the experimental design, the cells were divided into four groups, including untreated, ASA-treated, BTZ-treated and ASA+BTZ co-treated groups. The cells were then incubated for 24, 48 and 72 h at 37°C, respectively. Following treatment of the cells for indicated durations, Cell Counting Kit-8 (CCK-8) solution (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added (20 µl per well) and the cells were incubated for 2 h at 37°C. The plates were then read on an automated microplate spectrophotometer (DNM-9602; Perlong Medical Equipment Co., Ltd., Nanjing, China) at 450 nm.

**Cell apoptosis analysis.** In the cell apoptosis assay, Annexin-V-fluorescein isothiocyanate (FITC; 1:250) and propidium iodide (PI; 1 µg/ml) were used, according to the protocol of the Annexin V-FITC apoptosis assay kit (Beyotime Institute of Biotechnology). FITC specifically binds to the phosphatidyl serine residues on the cell membrane, whereas PI binds to DNA when the cell membrane becomes permeable. The cells were stained and analyzed using the FACSscan system (BD Biosciences, Franklin Lakes, NJ, USA). The data were analyzed using CellQuest (BD Biosciences) software. For each analysis, 10,000 events were recorded.

**Drug interaction analysis.** The ratio (R) was used to analyze the interaction of the ASA and BTZ combination in the two cell lines, as previously described (28). The R ratio was calculated as follows:

\[ R = \frac{\text{survival (ASA+BTZ)}}{\text{survival ASA} \times \text{survival BTZ}} \]

If R<0.8, the combination was considered to be synergistic; if 0.8<R<1.2, the combination was considered additive; if R>1.2, the combination was considered antagonistic.

**Western blot analysis.** The treated cells (5-6x10^6) were washed in PBS and then lysed in 2X Laemmli buffer. Protein concentrations were determined using the BCA assay kit.

Following boiling for 5 min, equivalent quantities of protein (30-40 µg) were separated on 8-12% SDS-polyacrylamide gels and then transferred onto a nitrocellulose membrane (0.45 µM). The membranes were blocked with 5% BSA in TBS/Tween20 (0.05% v/v) for 1 h, followed by incubation at 4°C overnight with primary antibodies against Bcl-2 (1:500 dilution), survivin (1:870 dilution), Akt (1:1,000 dilution), p-Akt (Thr308; 1:1,000 dilution) and p-Akt (Ser473; 1:1,000 dilution). The antimyeloma effect of BTZ, the first proteasome inhibitor to be approved by the Food and Drug Administration of USA in 2003, is well-recognized.
Results

Co-treatment of ASA and BTZ reduces the proliferation of myeloma cells. ASA at a dose of 2.5 mM was selected for use in experiments in the present study, as 2.5 mM was the concentration measured in the serum of patients treated with ASA for chronic inflammatory diseases in a previous study (29). A BTZ concentration of 10 nM was the plateau concentration following an initial peak at ~300 nM (for 1 h) in the serum of BTZ-treated patients with MM in a previous study (30). Therefore, 10 nM BTZ was used as the experimental concentration in the present study. The effects of ASA, BTZ and ASA in combination with BTZ on the proliferation of MM1.S and RPMI-8226 cells were evaluated using a CCK-8 assay.

As shown in Fig. 1A, MM1.S cells treated with ASA+BTZ for 24, 48 and 72 h led to significant decreases (P<0.05) in cell proliferation (78.3, 85.1 and 91.9%, respectively), compared with the cells treated with ASA alone (52.7, 64.6 and 72.8%, respectively) or BTZ alone (43.6, 64.1 and 75.1%, respectively). However, no significant difference was found between the ASA-treated and BTZ-treated groups.

As shown in Fig. 1B, treatment with ASA+BTZ significantly (P<0.05) reduced the viability of the RPMI-8226 cells within 24, 48 and 72 h (56.4, 73.9 and 88.5%, respectively), compared with the cells exposed to ASA alone (34.3, 56.1 and 63.6%, respectively) or BTZ alone (32.1, 42.9 and 68.4%, respectively). Again, no statistical differences were found between the ASA-treated and BTZ-treated groups (P>0.05).

The combination treatment of ASA and BTZ for 24, 48 and 72 h resulted in an additive effect on the inhibitory rate of MM1.S or RPMI-8226 cells, as R was between 0.8 and 1.2 in the two cell lines, indicating that ASA enhanced the antymyeloma activity of BTZ.

Co-exposure of ASA+BTZ augments the apoptotic rate of myeloma cells. The present study used Annexin V-FITC/PI flow cytometry to determine whether the additive action of ASA and BTZ was correlated with the induction of cell apoptosis. The MM1.S and RPMI-8226 cells were incubated with ASA alone, BTZ alone and ASA+BTZ for 24, 48 and 72 h, respectively. At each time point, the cell proliferation was determined using Cell Counting Kit-8 analysis. Data are presented as the mean ± standard deviation from independent experiments. P<0.05. ASA, aspirin; BTZ, bortezomib.

As shown in Fig. 2, the apoptotic rates of the untreated cells, and the cells treated with ASA alone, BTZ alone and with ASA and BTZ were 2.73, 44.8, 45.4 and 64.3%, respectively. Co-exposure of the cells to ASA with BTZ led to higher rates of apoptosis, compared with the cells treated with either ASA or BTZ alone (P<0.05). No significant differences were found between the ASA-treated group and BTZ-treated group.

In the RPMI-8226 cells, the apoptotic rates were 3.43, 36.1, 57.9 and 77.2% in the untreated, ASA-treated, BTZ-treated and ASA+BTZ-treated cells, respectively. Similarly, co-treatment with ASA and BTZ triggered higher rates of cell apoptosis, compared with either ASA or BTZ alone (P<0.05). Unlike the MM1.S cells, BTZ treatment induced higher rates of apoptosis, compared with ASA treatment in the RPMI-8226 cells (P<0.05). Taken together, these findings revealed that co-exposure to ASA and BTZ augmented the apoptotic rate of myeloma cells, compared with ASA or BTZ treatment alone in myeloma cells.

ASA inhibits the phosphorylation of AKT induced by BTZ in myeloma cells. AKT is important in the carcinogenesis of MM via controlling cell survival and apoptosis (31). Aberrant AKT activation confers chemoresistance to dexamethasone (Dex) and BTZ in MM cells (24). In particular, the phosphorylation of Thr308 and Ser473 is essential in the activation of AKT. Therefore, the present study examined the effect of ASA and
BTZ alone or in combination on the phosphorylation of AKT in myeloma cells over 48 h.

As shown in Fig. 3, the MM1.S and RPMI-8226 cells expressed high endogenous levels of p-AKT, indicating the constitutive activation of AKT in the two cell lines. ASA treatment markedly decreased the levels of p-AKT, including Thr308 and Ser473, in the MM1.S and RPMI-8226 cells. Of note, exposure of the two cell lines to ASA almost completely inhibited the phosphorylation of AKT at Thr308. However, no significant changes were found in total AKT protein between the two cell lines. In addition, it was found that BTZ treatment led to the enhancement of p-AKT, including Thr308 and Ser473. Treatment with ASA in combination with BTZ markedly reduced the phosphorylation of AKT, particularly for Thr308, suggesting the potential activity of ASA in overcoming the resistance to BTZ in myeloma cells.

**ASA downregulates the expression of survivin induced by BTZ.**

As a prominent anti-apoptotic molecule, increased levels of survivin contribute to uncontrolled cell proliferation and drug resistance in MM. Therefore; the present study investigated the effect of the ASA and BTZ combination on the level of survivin.

As shown in Fig. 4, exposure of the MM1.S and RPMI-8226 cells to ASA alone for 48 h led to significant decreases in survivin, compared with the untreated group. By contrast, BTZ treatment induced the upregulation of survivin in the MM1.S and RPMI-8226 cells. However, the combined treatment with ASA and BTZ decreased the protein levels of survivin in the MM1.S and RPMI-8226 cells, indicating that ASA may inhibit the upregulation of survivin triggered by BTZ.

**ASA in combination with BTZ suppresses the expression of Bcl-2 in myeloma cells.**

As a classical anti-apoptotic gene, Bcl-2 regulates apoptosis and cell death in MM, contributing to the pathogenesis, progression and chemoresistance of MM. Therefore, the present study examined the effect of treatment with ASA and/or BTZ on the protein expression of Bcl-2.

As shown in Fig. 5, incubation of the myeloma cells with ASA or BTZ for 48 h caused a marked downregulation in the level of Bcl-2, compared with the corresponding vehicle.
Notably, exposure of myeloma cells to ASA+BTZ markedly decreased the protein level of Bcl-2, compared with ASA or BTZ treatment alone. These results supported the causal association between the suppression of Bcl-2 protein and the apoptosis induced by ASA and/or BTZ in MM1.S and RPMI-8226 myeloma cells.

**Discussion**

At present, BTZ has been incorporated as leading agent into conditioning, consolidation and maintenance therapy for patients with MM (19). However, the prolonged administration of BTZ is associated with the development of drug resistance (20). The mechanisms underlying BTZ resistance in MM remain to be elucidated, however, they have been partly attributed to ‘molecular side-effects’, including the induction of AKT activation and upregulation of survivin (24), which attenuate the cytotoxic action of BTZ against MM cells and can lead to chemoresistance. Therefore, identifying how to enhance the antimielyoma activity of BTZ, particularly in patients with relapsed or refractory MM, is required. The
antineoplastic role of ASA has been verified in a wide range of solid tumor types (32-36). Our previous study reported that ASA exerted antimyeloma activity in vitro and in vivo accompanying the thrombophrophylactic profile (18). In the present study, the chemosensitive effect of ASA was examined in myeloma cells treated with BTZ based on the ‘molecular side-effects’.

The concentrations of 2.5 mM ASA and 10 nM BTZ were selected as the experimental concentrations in the present study, as they resemble the serum concentrations in patients with MM with important clinical implications (29,30). Initially, the present study found that ASA in combination with BTZ resulted in enhanced inhibition of cell proliferation, compared with ASA or BTZ alone in MM1.S and RPMI-8226 cells, and occurred in a time-dependent manner. Subsequent interaction analysis revealed an additive effect, indicating that ASA may potentiate the antimploma property of BTZ. In accordance, the co-administration of ASA and BTZ triggered higher apoptotic rates, compared with treatment with ASA or BTZ alone in the two cell lines. These results supported the hypothesis that ASA has a chemosensitive effect in BTZ-treated myeloma cells.

As a serine-threonine kinase, AKT is a key molecule of the phosphoinositide 3-kinase/AKT signaling pathway. Once recruited to the plasma membrane, AKT is activated by phosphorylation at the Ser473 and Thr308 residues, and then regulates the function of several cellular proteins involved in survival/apoptosis, differentiation and proliferation, including mammalian target of rapamycin, NF-κB and glycogen synthase kinase-3 (37). Several studies have provided evidence that the aberrant activation of AKT is important in the pathogenesis of various types of cancer, including MM (38-41). The ectopic activation of AKT has been documented in ~50% patients with MM. In addition, p-AKT renders anti-apoptotic activity to MM cells, indicating the importance of AKT activation in the carcinogenesis of MM (42). p-AKT is also associated with the prognosis in MM (38). These findings provide compelling evidence that AKT may be a potential therapeutic target in MM treatment. In the present study, treatment with ASA alone almost completely inhibited the phosphorylation of AKT (Thr308) and partly suppressed the phosphorylation of AKT (Ser473) in MM1.S and RPMI-8226 cells, indicating that AKT was the anticancer target of ASA in myeloma cells. By contrast, exposure of the myeloma cells to BTZ alone induced the phosphorylation of AKT, which was in agreement with a report by Hideshima et al (24). Of note, treatment with ASA combined with BTZ markedly inhibited the levels of p-AKT (Thr308 and Ser473), particularly for Thr308. These data suggested that ASA may augment the cytotoxic activity of BTZ against myeloma cells, and may even overcome the chemoresistance of BTZ in refractory/relapsed MM.

Survivin is also involved in inhibiting apoptosis, promoting proliferation and enhancing invasion in malignancies. Survivin has been reported to be overexpressed ubiquitously in cells in several types of cancer, including breast cancer (43), lung cancer (44) and MM (45). Furthermore, elevated levels of survivin have been correlated with poor prognosis, decreased survival and chemotherapy resistance in MM cells (45,46). Accordingly, the inhibition of survivin may be an efficient form of therapy in patients with MM. In the present study, it was demonstrated that BTZ alone was capable of increasing the level of survivin in MM1.S and RPMI-8226 cells, which was in accordance with the results reported in human non-small cell lung cancer cells by Liu et al (47). By contrast, the concurrent use of ASA and BTZ substantially inhibited the expression of survivin in the two cell lines. These findings provided convincing evidence that ASA may increase the cytotoxicity of BTZ to myeloma cells, in part, via the inhibition of survivin.

Cell apoptosis is correlated with a broad spectrum of cellular factors and pathophysiologic pathways. The Bcl-2 family is the most prominent in the process of apoptosis. In addition, Bcl-2, as a classical anti-apoptotic protein, has been confirmed to be overexpressed in a diverse range of types of cancer in humans (48-50). The Bcl-2 protein is expressed at high levels in patients with myeloma and is implicated in the regulation of chemosensitivity. Dex has been used for the treatment of MM for >50 years. Dex has also been incorporated into agents in combination with BTZ, thalidomide or lenalidomide. However, elevated expression of Bcl-2 confers chemoresistance to Dex in myeloma cells (51,52). In the present study, ASA exhibited antineoplastic activity against Dex-sensitive MM1.S cells and Dex-resistant RPMI-8226 cells. The western blot assay revealed that treatment with either ASA or BTZ alone downregulated the level of Bcl-2. Furthermore, ASA in combination with BTZ led to a marked decrease in the protein level of Bcl-2, compared with either ASA or BTZ alone, suggesting that ASA in combination with BTZ may be a promising treatment regimen for patients with MM with elevated expression of Bcl-2. Thus, the rationale of a combined regimen of Dex and BTZ in treating MM may be, in part, based on the ability of BTZ to inhibit Bcl-2. These findings indicated that BTZ may abrogate chemoresistance to Dex mediated by enhanced Bcl-2, which was consistent with reports by Ailawadhi et al (53) and Pei et al (54).

Perifosine (PERI), a novel synthetic alkylphospholipid, targets Akt and exerts potent antineoplastic activity in a wide variety of neoplasms, particularly MM and colorectal carcinoma (55). PERI also induces the significant downregulation of survivin in human myeloma cells (56). Clinical observations have found that a treatment regimen of PERI in combination with BTZ showed marked activity, with an overall response rate (ORR) of 32 and 65%, and median overall survival (mOS) of 22.5 and 30.4 months in BTZ-refractory and BTZ-relapsed patients, respectively (57). Encouraged by this data, a placebo-controlled phase III study was designed to evaluate the effect of adding PERI (50 mg daily) to BTZ and DEX in patients with MM who had relapsed following a BTZ-based regimen and who had received between one and four previous treatment regimens. However, this phase III experiment showed no benefit in PFS or ORR when PERI was added to BTZ and DEX in patients with resistant, relapsed and refractory MM. Furthermore, the mOS for PERI was 141.9 weeks and for the placebo was 83.3 weeks, which showed favorable results for PERI, but without statistical significance (P=0.356) (58), therefore, the investigation was discontinued.

Coincidently, in the present study, it was found that ASA also inhibited the expression of survivin and the phosphorylation of AKT induced by BTZ in myeloma cells, which explained the enhanced cytotoxicity of ASA+BTZ against
myeloma cells, compared with either agent alone. Notably, ASA retained its thromboprophylactic property, which was deficient in the case with PERI; treatment with PERI (150 mg daily) caused increased creatinine in 30-60% of patients with MM (59), whereas the continued administration of ASA may have a protective effect against renal injury (60). Thus, ASA may be a more superior candidate to augment the antymyeloma activity of BTZ, compared with PERI.

In conclusion, the present study demonstrated that the concurrent administration of ASA and BTZ caused higher levels of proliferative inhibition and apoptotic rates, compared with either agent alone in myeloma cells in vitro, which indicated the chemosensitivity towards ASA in MM treated by BTZ. The underlying mechanisms included the suppression of survivin and AKT phosphorylation by ASA induced by BTZ, together with the inhibition of Bcl-2, suggesting the potential of a regimen comprising ASA-BTZ-containing chemotherapy in patients with refractory or relapsed MM.

Acknowledgements

This study was funded by the National Nature Science Foundation of China (grant no. 81460037) and the Medical and Healthy Research Foundation of Nanjing Military Area of China (grant no. 14ZD31).

References

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu Q and He J: Cancer statistics in China, 2015. CA Cancer J Clin 66: 113-156, 2016.
3. Sonneveld P and Brodtkorb A: Treatment of relapsed and refractory multiple myeloma. Haematologica 101: 995, 2016.
4. Morgan GI and Davies FE: Role of thalidomide in the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol 1: (88 Suppl 1) S14-S22, 2013.
5. Bagatini T, Kastritis E, Politou M, Rousou M, Kostouros E, Gavriilopoulos A, Eleutherakis-Papaiakovou E, Kanelias N, Terpos E and Dimopoulos MA: Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol 88: 765-770, 2013.
6. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca A, Rossi D, Gentilini F, Cippa C, Galli M, et al: Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial. J Clin Oncol 29: 986-993, 2011.
7. Niesvizky R, Martínez-Navio D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Kastritis E, Roussou M, Kostouros E, Gavriilopoulos A, Eleutherakis-Papaiakovou E, Kanelias N, Terpos E and Dimopoulos MA: Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol 88: 765-770, 2013.
8. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca A, Rossi D, Gentilini F, Cippa C, Galli M, et al: Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial. J Clin Oncol 29: 986-993, 2011.
9. Niesvizky R, Martínez-Navio D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F, et al: Prophylactic low-dose aspirin is effective anti-thrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 48: 2330-2337, 2007.
10. Araujo JL, Altorki NK, Sonett JR, Rodriguez A, Sungur-Stasik K, Spinelli CF, Neugut AI and Abrams JA: Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients. Therap Adv Gastroenterol 9: 806-814.
11. Murphy C, Turner N, Wong HL, Sinnathamby M, Tice J, Lee B, Desai J, Skinner I, Christie M and Hutchinson R: Examining the impact of regular aspirin use and PI3KCA mutations on survival in stage 2 colon cancer. Intern Med J: Nov 1, 2016 (Epub ahead of print).
12. Hochmuth F, Jochem M and Schlattmann P: Meta-analysis of aspirin use and risk of lung cancer shows notable results. Eur J Cancer Prev 25: 259-268, 2016.
13. Bradley MC, Black A, Freedman AN and Barron TI: Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer 125: 2067-2075, 2016.
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 67: 4981-4988, 2007.

48. Geng M, Wang L and Li P: Correlation between chemosensitivity to antitumor drugs and Bcl-2 expression in gastric cancer. Int J Clin Exp Pathol 6: 2554-2559, 2013.

49. Du P, Cao H, Wu HR, Zha BS, Wang HW, Gu CW, Xing CG and Chen W: Blocking Bcl-2 leads to autophagy activation and cell death of the HEPG2 liver cancer cell line. Asian Pac J Cancer Prev 14: 5849-5854, 2013.

50. Yang D, Chen MB, Wang LQ, Yang L, Liu CY and Lu PH: Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: A systematic review and meta-analysis. J Exp Clin Cancer Res 32: 105, 2013.

51. Iyer R, Ding L, Batchu RB, Naugler S, Shammas MA and Munshi NC: Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Leuk Res 27: 73-78, 2003.

52. Gazitt Y, Fey V, Thomas C and Alvarez R: Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 13: 397-405, 1998.

53. Ailawadi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, et al: Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 53: 1174-1182, 2012.

54. Pei XY, Dai Y and Grant S: The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17: 2036-2045, 2003.

55. Vink SR, Schellen JSJH, van Blitterswijk WJ and Verheij M: Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 23: 279-286, 2005.

56. Hideshima T, Catley L, Raje N, Chauhan D, Poddar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, et al: Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138: 783-791, 2007.

57. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Denismore J, Krishnan A, Raje N, Bar M, et al: Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase II/III trial. J Clin Oncol 29: 4243-4249, 2011.

58. Richardson PG, Nagler A, Dina BY and Ashraf Badros: Randomized placebo-controlled phase III study of perifosine combined with bortezomib and dexamethasone in relapsed, refractory multiple myeloma patients previously treated with bortezomib. ASH Annual Meeting abstract 3189, 2013.

59. Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, et al: Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: A phase I multiple myeloma research consortium study. Br J Haematol 158: 472-480, 2012.

60. G errah R, Ehrlich S, Tshiori S and Sahar G: Beneficial effect of aspirin on renal function in patients with renal insufficiency postcardiac surgery. J Cardiovasc Surg (Torino) 45: 545-550, 2004.